Key Details
Price
$26.30Annual ROE
29.38%Beta
-0.44Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 26, 2024Analyst ratings
Recent major analysts updates
24 Oct '24 Raymond James
Strong Buy11 Sept '24 Wells Fargo
Overweight17 June '24 Guggenheim
Buy21 May '24 Leerink Partners
Outperform11 Apr '24 Oppenheimer
Outperform02 Apr '24 Piper Sandler
OverweightMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Q32 Bio doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 91.69%: Read This Before Placing a Bet
QTTB
zacks.com12 August 2024
The consensus price target hints at a 91.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Q32 Bio Joins Russell 3000® Index
QTTB
prnewswire.com01 July 2024
WALTHAM, Mass. , July 1, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that the company is joining the broad-market Russell 3000® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.
FAQ
- What is the primary business of Q32 Bio?
- What is the ticker symbol for Q32 Bio?
- Does Q32 Bio pay dividends?
- What sector is Q32 Bio in?
- What industry is Q32 Bio in?
- What country is Q32 Bio based in?
- When did Q32 Bio go public?
- Is Q32 Bio in the S&P 500?
- Is Q32 Bio in the NASDAQ 100?
- Is Q32 Bio in the Dow Jones?
- When was Q32 Bio's last earnings report?
- When does Q32 Bio report earnings?
- Should I buy Q32 Bio stock now?
What is the primary business of Q32 Bio?
QTTB, part of Q32 Bio, focuses on developing innovative therapies for autoimmune diseases. The company uses advanced technology to create treatments that target specific immune responses, aiming to improve patients' quality of life and reduce side effects compared to traditional therapies.
What is the ticker symbol for Q32 Bio?
The ticker symbol for Q32 Bio is NASDAQ:QTTB
Does Q32 Bio pay dividends?
No, Q32 Bio does not pay dividends
What sector is Q32 Bio in?
Q32 Bio is in the Healthcare sector
What industry is Q32 Bio in?
Q32 Bio is in the Biotechnology industry
What country is Q32 Bio based in?
Q32 Bio is headquartered in United States
When did Q32 Bio go public?
Q32 Bio's initial public offering (IPO) was on 28 March 2018
Is Q32 Bio in the S&P 500?
No, Q32 Bio is not included in the S&P 500 index
Is Q32 Bio in the NASDAQ 100?
No, Q32 Bio is not included in the NASDAQ 100 index
Is Q32 Bio in the Dow Jones?
No, Q32 Bio is not included in the Dow Jones index
When was Q32 Bio's last earnings report?
Q32 Bio's most recent earnings report was on 7 November 2024
When does Q32 Bio report earnings?
The next expected earnings date for Q32 Bio is 28 February 2025
Should I buy Q32 Bio stock now?
As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions